Founders Face Pressure From All Sides as Biotech Crawls Toward Recovery

Why It Matters

Reduced funding threatens the pipeline of new therapies, while the shift toward AI‑centric deals reshapes biotech’s innovation dynamics.

Key Takeaways

• Interest‑rate hikes have shifted capital toward late‑stage exits, not early biotech
• Altitude Lab provides space, mentorship, and investor access for struggling founders
• Denali’s Avlayah approval shows breakthroughs can still attract attention despite market headwinds
• Non‑traditional investors, like a baseball‑team owner, are filling early‑stage funding gaps
• Founders are “building in public” via blogs to generate venture interest

Pulse Analysis

The biotech sector is navigating a funding drought that stems from broader macroeconomic pressures. Rising interest rates have made capital expensive, prompting investors to prioritize late‑stage exits and AI‑driven ventures over nascent drug programs. This risk‑averse climate contrasts sharply with the 2019‑21 boom when capital flowed freely into early‑stage biology, and it has forced founders to sharpen their storytelling and demonstrate tangible milestones at every investor touchpoint.

In response, regional accelerators such as Salt Lake City’s Altitude Lab are becoming lifelines for fledgling companies. By offering lab space, mentorship, and curated pitch events, they help founders bridge the gap between scientific discovery and market validation. Unconventional backers—ranging from sports franchise owners to community angels—are also stepping in, providing seed checks that keep projects alive while traditional venture firms remain cautious. The experiences of Eris Biotech’s Evita Weagel and AI‑lab platform Elnora’s Carmen Kivisild illustrate how community‑driven funding and transparent, public‑facing development can attract attention despite the broader squeeze.

Looking ahead, the industry’s cyclical nature suggests a rebound is plausible, but the recovery will likely be uneven. Companies that can demonstrate clear regulatory progress, such as Denali Therapeutics’ recent FDA approval of Avlayah, will stand out and attract recycled capital from successful exits. Meanwhile, founders must continue to adopt hybrid strategies—leveraging accelerators, building public narratives, and courting non‑traditional investors—to sustain innovation pipelines until the market sentiment shifts back toward early‑stage biotech. The next wave of breakthroughs will depend as much on savvy fundraising as on scientific merit.